Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer

Androgen deprivation therapy is the mainstay of treatment of advanced prostate cancer (PCa). However, a significant portion of patients experience disease relapse and tumors ultimately evolve into castration resistant prostate cancer (CRPC), for which there is no cure in the clinic. The Polycomb pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Changping, Jin, Xin, Yang, Jing, Yang, Yinhui, He, Yundong, Ding, Liya, Pan, Yunqian, Chen, Shuai, Jiang, Jingting, Huang, Haojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823118/
https://www.ncbi.nlm.nih.gov/pubmed/26657505
http://dx.doi.org/10.18632/oncotarget.6497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823118/
https://www.ncbi.nlm.nih.gov/pubmed/26657505
http://dx.doi.org/10.18632/oncotarget.6497

Ejemplares similares